The effects of vitamin K1 and vitamin K2 on the proliferation, cytokine production and regulatory T‐cell frequency in peripheral blood mononuclear cells of paediatric atopic dermatitis patients

Abstract

We estimated the pharmacological efficacy of vitamin K (VK ) and VK on the mitogen-activated peripheral blood mononuclear cells (PBMCs) of paediatric atopic dermatitis (AD) patients. VK suppressed the in vitro proliferation of T-cell mitogen-activated PBMCs of AD patients. In contrast, VK had little effect on the PBMC proliferation. The IL-2 production from the activated PBMCs of AD patients significantly increased (P < .05), while the production significantly decreased by 100 μmol L VK (P < .01). In addition, 100 μmol L VK reduced the percentage of CD4+ and CD4+CD25+ cells in PBMCs. These results suggest that VK2 can modulate T-cell function in PBMCs of AD patients.

Cytotoxic effects of vitamins K1, K2, and K3 against human T lymphoblastoid leukemia cells through apoptosis induction and cell cycle arrest

“…Our previous studies highlighted the immunosuppressive effects of vitamins K2 and K3 (Hatanaka et al, 2014;Kusano et al, 2018;Meng et al, 2018;Xu, Meng, Wu, et al, 2019). In the present study, we compared the cytotoxic effects of vitamins K1, K2, and K3 on viabilities of T-cell mitogen-activated PBMCs (Figure 9 and Table 1).…”

Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease

“…Furthering this finding, K2 decreases proliferation of T-cells from healthy individuals, whereas vitamin K1 had no such effect [103]. This has been further substantiated with T-cells from a larger number of children with pediatric atopic dermatitis and healthy controls, as well as a separate study with patients on dialysis [104,105]. Both these studies demonstrated that K2 decreased the number of activated T-cells, as well as proliferation.…”

Vitamin K2 Suppresses Proliferation and Inflammatory Cytokine Production in Mitogen-Activated Lymphocytes of Atopic Dermatitis Patients through the Inhibition of Mitogen-Activated Protein Kinases

“…[17][18][19] We have previously reported that vitamin Ks have effectively suppress the proliferation of T cell mitogen-activated PBMCs of pediatric atopic dermatitis patients. 14) The present study was carried out to investigate the implications of the regulation of mitogen-activated protein kinase, a signaling-molecule, on the suppressive efficacy of Differences in the amounts of Th1/Th2/Th17 cytokines in the plasma and culture supernatant of PBMCs (CS) between healthy subjects (n = 13) and AD patients (n = 10) were analyzed by Wilcoxon's signed-rank test. In the case of IL-4, a significant difference was observed between the two subject groups.…”

“…The results showed that vitamin K2 at 10-100 µM significantly suppressed the T-cell proliferative response and modulated Th1/Th2/Th17 cytokine production in T cell mitogen-activated PBMCs derived from healthy subjects and pediatric atopic dermatitis patients, which are consistent with our previous findings. 13,14) In our previous study, we examined the suppressive effects of vitamin Ks by MTT assays. 14) In the present study in addition to the MTT assay, we confirmed the vitamin K2 efficacy by Calcein AM/PI double staining followed by cell counting.…”

“…We previously reported that vitamin Ks effectively suppress the proliferation and production of inflammatory cytokines from human peripheral-blood mononuclear cells (PBMCs) activated by T cell mitogen. 12,13) We also examined the effects of VKs on the proliferation and regulatory T cell-frequency in the PBMCs of pediatric atopic dermatitis patients. 14) Among the vitamin Ks that we examined in these studies, vitamin K2 is generally used for the treatment of osteoporosis, and we therefore considered that vitamin K2 would be a candidate therapeutic agent for the safe and efficient treatment of atopic dermatitis.…”